Pentavalent Vaccine Composition
The pentavalent vaccine combines five vaccines into a single formulation: diphtheria toxoid, tetanus toxoid, acellular pertussis (DTaP), Haemophilus influenzae type b (Hib) conjugate, and hepatitis B (HepB). 1, 2
Detailed Components of Pentavalent Vaccine
The pentavalent vaccine contains:
- Diphtheria toxoid - Provides immunity against diphtheria
- Tetanus toxoid - Provides immunity against tetanus
- Acellular pertussis antigens - Provides immunity against whooping cough
- Hepatitis B surface antigen - Provides immunity against hepatitis B virus
- Haemophilus influenzae type b conjugate - Provides immunity against Hib disease
Available Pentavalent Vaccine Formulations
As of 2020, there were two pentavalent combination vaccines licensed for use in the infant vaccine series in the United States 1:
DTaP-HepB-IPV (Pediarix) - Manufactured by GlaxoSmithKline
- Contains diphtheria and tetanus toxoids, acellular pertussis, hepatitis B, and inactivated poliovirus
- Licensed for use in children aged 6 weeks through 6 years
DTaP-IPV/Hib (Pentacel) - Manufactured by Sanofi Pasteur
- Contains diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type b conjugate
- Licensed for use in children aged 6 weeks through 4 years
- Supplied as a two-component product: DTaP-IPV component as a liquid and Hib component as a lyophilized powder that requires reconstitution 2
Clinical Considerations
- Pentavalent vaccines reduce the number of injections required, improving vaccination coverage rates and compliance 1, 2
- The Advisory Committee on Immunization Practices (ACIP) generally prefers combination vaccines over separate injections of equivalent component vaccines 1
- These vaccines can be administered as early as 6 weeks of age as part of the routine childhood immunization schedule 1
- Pentavalent vaccines have demonstrated comparable immunogenicity to separately administered component vaccines 2
Important Considerations
- The pentavalent vaccines should not be used for booster doses at age 4-6 years 2
- A higher rate of fever may be observed with combination vaccines compared to individual component vaccines, though rates of fever-related medical events remain similar 1
- The vaccines can be administered simultaneously with other childhood vaccines without compromising immunogenicity or safety 2
Newer Developments
In 2018, a hexavalent vaccine (DTaP-IPV-Hib-HepB) was approved, which contains all components of the pentavalent vaccine plus inactivated poliovirus, offering protection against six diseases with a single injection 1.
The pentavalent vaccine has significantly improved childhood immunization programs by reducing the number of injections needed while maintaining effective protection against multiple serious infectious diseases.